Approval · Notice of Compliance 30346 · 2023
PREVACID: Notice of Compliance 30346
Issued March 16, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30346
- Date
- March 16, 2023
- Company
- Takeda Pharmaceuticals America IncCambridge, Massachusetts, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) with new safety information about Severe Cutaneous Adverse Reactions (SCARs)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREVACID | Not yet assigned | — |
| PREVACID FASTAB | Not yet assigned | — |
Medicinal ingredients
- LANSOPRAZOLE 15 MG per CAP
- LANSOPRAZOLE 30 MG per CAP
- LANSOPRAZOLE 15 MG per TAB
- LANSOPRAZOLE 30 MG per TAB